ArticleInternational journal of molecular sciences2026
Tracking of Neuroinflammation Dynamics During Combined Anti-β-Amyloid Therapy (AAT) and Immunomodulation in a Preclinical Alzheimer's Disease Model.
Karin Wind-Mark, Lea H Kunze, Michael Willem, Giovanna Palumbo, Camilla Giudici, Brigitte Nuscher, Guido Boening, Franz J Gildehaus, Simon Lindner, Rudolf A Werner and 4 more
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Karin Wind-MarkDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.
Lea H KunzeDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0003-4669-2113 Michael WillemBiomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, 81377 Munich, Germany.
Giovanna PalumboDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0001-9467-2761 Camilla GiudiciGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.
Brigitte NuscherBiomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, 81377 Munich, Germany.
Guido BoeningDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0003-0986-2929 Franz J GildehausDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0002-6830-1817 Simon LindnerDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.
Rudolf A WernerDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0003-3372-6046 Nicolai FranzmeierMunich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.
Johannes S GnörichDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0003-1554-7765 Matthias BrendelDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0002-9247-2843 Artem ZatcepinDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0002-0224-088X Funding
German Research Foundation EXC 2145 SyNergy - ID 390857198Ludwig Maximilian University of Munich Medical & Clinician Scientist Program (MCSP)
6 · The paper itselfAbstract
Neuroinflammation is increasingly recognized as a key modulator of therapeutic response and adverse events in Alzheimer's disease (AD), especially during anti-amyloid-β (Aβ) monoclonal antibody (Aβ-mAb) treatment. We applied longitudinal translocator protein (TSPO) positron emission tomography (PET) to evaluate TSPO-associated neuroinflammatory responses to chronic Aβ-mAb therapy and their modulation by the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone. App
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, MonoclonalImmunomodulationNeuroinflammatory DiseasesAnimalsBrainDisease Models, AnimalMiceMice, TransgenicMicrogliaPioglitazonePositron-Emission TomographyPPAR-gamma AgonistsReceptors, GABAAmyloid beta-PeptidesAntibodies, MonoclonalBzrp protein, mousePioglitazonePPAR-gamma AgonistsReceptors, GABAAlzheimer’s diseasedesynchronization indexmicrogliamonoclonal antibodyneuroinflammationpioglitazoneTSPO-PET
Identifiers
PMID42196607
PMCPMC13206848
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390